Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®)‎ in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema

Abstract EN

Purpose.

To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in patients with cataract and diabetic macular edema.

Methods.

In this two-center, retrospective, single-group study, the charts of 16 consecutive patients who underwent combined phacoemulsification and intravitreal dexamethasone implant were retrospectively reviewed.

These 16 patients, 7 men and 9 women, were observed at least 3 months of follow-up.

Primary outcome was the change of the central retinal thickness (CRT); secondary outcome was the change of best-corrected visual acuity (BCVA).

Any ocular complications were recorded.

Results.

Mean CRT decreased significantly from 486 ± 152.4 μm at baseline to 365.5 ± 91 μm at 30 days (p=.005), to 326 ± 80 μm at 60 days (p=.0004), and to 362 ± 134 μm at 90 days (p=.001).

Mean BCVA was 20/105 (logMAR, 0.72 ± 0.34) at baseline and improved significantly (p≤.007) at all postsurgery time points.

One case of ocular hypertension was observed and successfully managed with topical therapy.

No endophthalmitis or other ocular complications were observed.

Conclusion.

Intravitreal slow-release dexamethasone implant combined with cataract surgery may be an effective approach on morphologic and functional outcomes for patients with cataract and diabetic macular edema for at least three months after surgery.